Monoclonal antibodies provide protection against a wide range of infectious microbes, and now, in a series of elegant ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and ...

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

Two new drugs for Alzheimer’s have been rejected for use on the NHS. They slow progression of the disease, but they can have ...

Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 ...

Results from a phase 1 study showed TEV-53408 reduced free serum IL-15 levels in healthy participants. The Food and Drug Administration (FDA) has granted Fast Track designation to TEV-53408, an ...

The wild type enzyme elicits potent anti-drug antibodies (ADA) that significantly impact redosing, whereas in a preclinical redosing model Cyrus’ candidate exhibits potent activity on repeat doses ...

She was enrolled in a clinical trial evaluating ivermectin (an anti-parasite drug with immune stimulatory activity) and balstilimab (an immunotherapy) with limited success. She is currently enrolled ...

The extension study found that anti-drug antibodies and undetectable drug levels were associated with both treatment without an accompanying immunomodulator and carriage of the HLA-DQA1*05 genetic ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Tecentriq), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ...

These manifestations led to the formation of immune complexes between brolucizumab and anti-drug antibodies. Karle and Kearns, along with their colleagues, caution that more work is needed for ...